Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer is mediated by the C797S/T790M/activating mutation. Here, the authors identify brigatinib as a potential drug that in combination with anti-EGFR can overcome resistance in mutated cells.

Bibliographic Details
Main Authors: Ken Uchibori, Naohiko Inase, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Format: Article
Language:English
Published: Nature Publishing Group 2017-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms14768
id doaj-7e03180accc34d52b7997deb52cfee5f
record_format Article
spelling doaj-7e03180accc34d52b7997deb52cfee5f2021-05-11T07:12:07ZengNature Publishing GroupNature Communications2041-17232017-03-018111610.1038/ncomms14768Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancerKen Uchibori0Naohiko Inase1Mitsugu Araki2Mayumi Kamada3Shigeo Sato4Yasushi Okuno5Naoya Fujita6Ryohei Katayama7Cancer Chemotherapy Center, Japanese Foundation for Cancer ResearchDepartment of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityRIKEN Advanced Institute for Computational ScienceGraduate School of Medicine, Kyoto UniversityCancer Chemotherapy Center, Japanese Foundation for Cancer ResearchRIKEN Advanced Institute for Computational ScienceCancer Chemotherapy Center, Japanese Foundation for Cancer ResearchCancer Chemotherapy Center, Japanese Foundation for Cancer ResearchResistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer is mediated by the C797S/T790M/activating mutation. Here, the authors identify brigatinib as a potential drug that in combination with anti-EGFR can overcome resistance in mutated cells.https://doi.org/10.1038/ncomms14768
collection DOAJ
language English
format Article
sources DOAJ
author Ken Uchibori
Naohiko Inase
Mitsugu Araki
Mayumi Kamada
Shigeo Sato
Yasushi Okuno
Naoya Fujita
Ryohei Katayama
spellingShingle Ken Uchibori
Naohiko Inase
Mitsugu Araki
Mayumi Kamada
Shigeo Sato
Yasushi Okuno
Naoya Fujita
Ryohei Katayama
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
Nature Communications
author_facet Ken Uchibori
Naohiko Inase
Mitsugu Araki
Mayumi Kamada
Shigeo Sato
Yasushi Okuno
Naoya Fujita
Ryohei Katayama
author_sort Ken Uchibori
title Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_short Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_full Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_fullStr Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_full_unstemmed Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_sort brigatinib combined with anti-egfr antibody overcomes osimertinib resistance in egfr-mutated non-small-cell lung cancer
publisher Nature Publishing Group
series Nature Communications
issn 2041-1723
publishDate 2017-03-01
description Resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer is mediated by the C797S/T790M/activating mutation. Here, the authors identify brigatinib as a potential drug that in combination with anti-EGFR can overcome resistance in mutated cells.
url https://doi.org/10.1038/ncomms14768
work_keys_str_mv AT kenuchibori brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer
AT naohikoinase brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer
AT mitsuguaraki brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer
AT mayumikamada brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer
AT shigeosato brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer
AT yasushiokuno brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer
AT naoyafujita brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer
AT ryoheikatayama brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer
_version_ 1721452690952683520

Similar Items